Canaccord lowered the firm’s price target on Neurogene (NGNE) to $180 from $200 and keeps a Buy rating on the shares. The firm updated its model for 4Q25 results, company commentary and incorporated their newly launched Rett disease model on the back of our recent KOL call
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGNE:
- Buy Rating Backed by Strong NGN-401 Clinical Progress, De-Risking Efficacy Data, and Solid Cash Runway in Rett Syndrome
- Buy Rating Underpinned by De-Risked NGN‑401 Development, Aligned Manufacturing Strategy, and Cash Runway Through Key 2027–28 Catalysts
- Neurogene Advances Rett Gene Therapy Toward BLA With Strong Cash Runway
- 1 Top Stock to Buy Now with 350% Upside, 3/24/2026, According to Top Analysts
- Midday Fly By: Estee Lauder in deal talks with Puig, Smithfield reports Q4 beat